Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: Treatment strategies for small pancreatic neuroendocrine tumors (PNETs) <2 cm in size are still under debate. The feasibility and safety of EUS-guided ethanol ablation (EUS-EA) have been demonstrated. However, sample sizes in previous studies were small with no comparative studies on surgery. Therefore, we aimed to compare the safety and long-term outcomes of EUS-EA with those of surgery for the management of nonfunctioning small PNETs.
Methods: We retrospectively reviewed patients with PNETs who were managed by EUS-EA (from 2011 to 2018) and surgery (from 2000 to 2018) at Asan Medical Center. Propensity score matching (PSM) was performed to increase comparability. The primary outcome was early and late major adverse events (Clavien-Dindo grade ≥III) after treatment. Secondary outcomes were 10-year overall (OS) and disease-specific survival (DSS) rates, length of hospital stay, and development of endocrine pancreatic insufficiency.
Results: Of all patients, 97 and 188 patients were included in the EUS-EA and surgery groups, respectively. PSM created 89 matched pairs. EUS-EA was associated with a significantly lower rate of early major adverse events (0% vs 11.2%, P = .003). Late major adverse events occurred more frequently after surgery, with no significant difference between groups (3.4% vs 10.1%, P = .07). Both treatment modalities showed comparable 10-year OS and DSS rates. The length of hospital stay was significantly shorter in the EUS-EA group (4 days vs 14.1 days, P < .001), and endocrine pancreatic insufficiency was less common after EUS-EA than after surgery (33.3% vs 48.6%, P = .121).
Conclusions: EUS-EA had fewer adverse events and a shorter hospital stay with similar OS and DSS rates compared with surgery, suggesting that EUS-EA may be a preferred alternative to surgical resection in selected patients with nonfunctioning small PNETs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gie.2022.11.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advanced NSCLC with leptomeningeal metastasis: Diagnostic and therapeutic challenges: A case report.
Radiol Case Rep
November 2025
Radiologist Consultant, Head of Radiology Department, An-Najah National University Hospital, Nablus, Palestine.
Lung cancer, particularly non-small lung cancer (NSCLC), is one of the most common malignant tumors worldwide and is associated with high mortality in advanced stages. Lung adenocarcinoma is the most frequent NSCLC subtype. Among these common metastatic sites, brain metastases and leptomeningeal metastases have a particularly debilitating impact on patients' survival and quality of life.
View Article and Find Full Text PDFLONP1 Promotes Hepatocarcinogenesis by Degrading ACO2 to Alleviate Ferroptosis.
Front Biosci (Landmark Ed)
August 2025
Department of Hepatobiliary and Pancreatic Surgery, Peking University Shenzhen Hospital, 518036 Shenzhen, Guangdong, China.
Background: Lon protease 1 (LONP1), an adenosine triphosphate (ATP)-dependent protease encoded by nuclear DNA that is highly conserved, maintains the mitochondrial protein balance and regulates adaptive responses to cellular stress. LONP1 dysfunction ultimately results in various forms of cellular and tissue damage. The function of LONP1 in hepatocellular carcinoma (HCC) and how it affects HCC growth were investigated in this work.
View Article and Find Full Text PDFFunctions and Mechanisms of Diabetes-Linked Transcription Factors.
Front Biosci (Landmark Ed)
August 2025
School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Transcription factors are significant regulators of gene expression in most biological processes related to diabetes, including beta cell (β-cell) development, insulin secretion and glucose metabolism. Dysregulation of transcription factor expression or abundance has been closely associated with the pathogenesis of type 1 and type 2 diabetes, including pancreatic and duodenal homeobox 1 (), neurogenic differentiation 1 (), and forkhead box protein O1 (). Gene expression is regulated at the transcriptional level by transcription factor binding, epigenetically by DNA methylation and chromatin remodelling, and post-transcriptional mechanisms, including alternative splicing and microRNA (miRNA).
View Article and Find Full Text PDFENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy.
Cell Rep Med
August 2025
Department of Biochemistry, Stanford University, Stanford, CA 94305, USA; ChEM-H Institute, Stanford University, Stanford, CA 94305, USA; Arc Institute, Palo Alto, CA 94304, USA. Electronic address:
Only one in five patients respond to immune checkpoint inhibitors, which primarily target adaptive immunity. Ectonucleotide pyrophosphatase/phophodiesterase 1 (ENPP1), the dominant hydrolase of 2'3'-cyclic-GMP-AMP (cGAMP) that suppresses downstream stimulator of interferon genes (STING) signaling, has emerged as a promising innate immunotherapy target. However, existing ENPP1 inhibitors have been optimized for prolonged systemic residence time rather than effective target inhibition within tumors.
View Article and Find Full Text PDFEnhancing the Diagnostic Performance of Repeated Endoscopic Ultrasound-Guided Tissue Acquisition Combined with Surrogate Repeated Endoscopic Retrograde Pancreatography for Small Pancreatic Cancer.
Dig Dis Sci
September 2025
Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.
Purpose: Diagnosing pancreatic tumors ≤ 10 mm is challenging due to limited visualization and low sampling sensitivity. This study aimed to evaluate the cumulative diagnostic performance of repeated endoscopic ultrasound-guided tissue acquisition (EUS-TA) and surrogate repeated endoscopic retrograde pancreatography (ERP).
Methods: This study analyzed 40 patients with suspected pancreatic tumors ≤ 10 mm who underwent EUS-TA and/or ERP retrospectively.